Provista Blog > Imaging + ? = improved breast cancer detection
Mammography has known limitations, especially when considering dense breast patients or patients who fall into the gray zone. But, what if there was a different way of looking at breast cancer that did not rely on visual interpretation and allowed healthcare providers to detect breast cancer irrespective of difficult-to-interpret findings?
In an effort to accomplish improved breast cancer detection, complementary blood-based approaches are being developed to help address the current limitations of imaging. By utilizing new detection strategies, healthcare providers will be able to improve the accuracy of breast cancer detection and minimize the consequences of false positive and negative results.
When combined with imaging, a liquid biopsy approach would improve diagnostic accuracy and provide greater confidence and clarity when clinical assessment is challenging. A blood based approach is based on physiology not anatomy, making it a vital tool in the detection process for women with dense breast or difficult-to-interpret findings.
Unlike genetic testing which determines the future risk of developing breast cancer, a blood-based approach would detect real-time disease status.
It is time, now to complement the standard-of-care for breast cancer detection by incorporating a blood-based approach. In order to detect and rule out breast cancer in women with difficult-to-interpret findings, we need look at this new approach!
At Provista Diagnostics, our mission is to develop world-class diagnostic tests for indications in breast and gynecologic cancers. As a leading diagnostics company, our aim is to create, produce and market innovative solutions for unmet clinical needs. Our products and services help to diagnose diseases and inform better clinical decisions, thus enhancing women’s health and quality of life. We do this in a responsible and ethical manner with a commitment to excellence in every aspect of our business.